How well the HPV vaccine works in people with weakened immune systems
Official title: Effectiveness of the HPV Vaccine in Immunocompromised Populations
Funded at Kaiser Foundation Research Institute · NIH-11135396 · Data updated 2026-11-12
This study is looking at how well the HPV vaccine works for people with weakened immune systems, like those with HIV or who have had organ transplants, to see if it can help prevent HPV-related cancers in these high-risk groups.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Kaiser Foundation Research Institute NIH-funded |
| Lab location | 1 site (Oakland, UNITED STATES) |
| Project start | July 9, 2024 |
| Project end | May 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $827,605 |
| NIH project number | 5R01AI186576-02 |
| Project ID | NIH-11135396 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals with HIV, autoimmune conditions, or those who have received organ transplants.
✕Less likely to help
Patients who are immunocompetent or do not have a history of immunocompromising conditions may not benefit from this research.
What this research studies
This research investigates the effectiveness of the HPV vaccine specifically in immunocompromised individuals, such as those living with HIV, autoimmune diseases, or those who have undergone organ transplants. The study aims to evaluate how well the vaccine prevents HPV-related diseases in these high-risk populations, as previous studies have primarily focused on vaccine safety and immune response rather than its actual effectiveness. By conducting a cohort study across two health systems, the research will gather data on the vaccine's ability to prevent conditions like cervical and anal cancers in these vulnerable groups.
Why it matters
Potential benefit: If successful, this research could lead to improved vaccination strategies that significantly reduce HPV-related diseases in immunocompromised patients.
How similar studies have gone: While there have been limited trials assessing HPV vaccine effectiveness in immunocompromised populations, this research aims to fill significant gaps and is considered novel in its approach.
Where this research is happening
-
Kaiser Foundation Research Institute
Oakland, United States Active
Researchers
- Principal investigator: Silverberg, Michael J — Kaiser Foundation Research Institute
- Study coordinator: Silverberg, Michael J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.